Oral vasodilator

Minoxidil (Oral)

Oral minoxidil has an average plasma half-life of 4.2 hours in man, with plasma levels of the parent drug reaching their maximum within the first hour, according to the US minoxidil tablet label.1

Strong evidenceGet the app

Level after one dose

Minoxidil (Oral) after one dose: 50% at ~4.2 h, 25% at 8.4 h, 12.5% at 12.6 h.

Drawn from the half-life in the app's model, ~4.2 h. The model's figures

Oral minoxidil is minoxidil taken as a tablet. The US tablet label calls it "an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance".1 The label states that minoxidil tablets "are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs", and that "Use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication."1

Oral minoxidil is also studied for hair loss. A search of PubMed on 16 November 2026 for "oral minoxidil" in the title or summary text returned 312 records, 5 of them typed as randomized controlled trials. A 2020 systematic review of 14 studies and 442 patients reported doses between 0.25 and 5 mg for eight types of alopecia, against a label dosage range for hypertension of usually 10 to 40 mg per day.2,1

The app lists oral minoxidil with a half-life of about 4.2 hours, 95% bioavailability, a typical dose of 2.5 to 5 mg per day and a peak at about 1 hour. The sections below set the label's and the studies' own figures beside these.

The label describes the blood pressure mechanism: "Reduction of peripheral arteriolar resistance and the associated fall in blood pressure trigger sympathetic, vagal inhibitory, and renal homeostatic mechanisms, including an increase in renin secretion, that lead to increased cardiac rate and output and salt and water retention."1 On hair, the label states: "No endocrine abnormalities have been found to explain the abnormal hair growth; thus, it is hypertrichosis without virilism."1

A 2022 review by Pietrauszka and Bergler-Czop in Postepy Dermatologii i Alergologii states: "Minoxidil is a pro-drug requiring bio-activation into minoxidil sulfate. The enzyme that catalyses this reaction in the hair follicle is minoxidil sulfotransferase (SULT1A1)."3 In a 2024 study by Jimenez-Cauhe and colleagues in the Journal of Cosmetic Dermatology, 41 patients with androgenetic alopecia took low-dose oral minoxidil for 6 months and hair follicle sulfotransferase activity was assayed in plucked follicles; 26 (63.4%) patients had a clinical improvement (19 of 26 men, 73.1%, and 6 of 15 women, 40.0%, figures that add to 25), and the response rate was 85% in patients with low follicle enzyme activity against 43% in those with high activity (p = 0.009). All 41 patients received oral minoxidil, and the authors write that low activity "is associated with a favorable response".4

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~4.2 h
Bioavailability
95%
Typical dose
2.5–5 mg/day
Route
Oral
Time to peak
~1 h

The app's half-life matches the label's; the label puts the plasma peak within the first hour where the app lists about 1 hour, and gives an absorption figure where the app lists bioavailability.1

Table 3.1Pharmacokinetics6 rows
ParameterApp's figureLabel figure
Half-life~4.2 hours"The average plasma half-life in man is 4.2 hours."1
Time to peak~1 hour"Plasma levels of the parent drug reach maximum within the first hour and decline rapidly thereafter."1
Bioavailability95%The label gives absorption: "at least 90% absorbed from the GI tract in experimental animals and man".1
MetabolismNo figure in the app"Approximately 90% of the administered drug is metabolized, predominantly by conjugation with glucuronic acid at the N-oxide position in the pyrimidine ring".1
Metabolites and bindingNo figure in the app"Known metabolites exert much less pharmacologic effect than minoxidil itself; all are excreted principally in the urine." Minoxidil "does not bind to plasma proteins and does not cross the blood brain barrier."1
Duration of blood pressure effectNo figure in the appAfter an effective single oral dose blood pressure "reaches a minimum between 2 and 3 hours" and "The total duration of effect is approximately 75 hours."1

The label adds that "The extent and time-course of blood pressure reduction by minoxidil do not correspond closely to its concentration in plasma."1 The 4.2 hour figure is a plasma half-life, and the label's 75 hours describes the blood pressure effect in patients treated for hypertension.1

Adams and colleagues (Biopharmaceutics and Drug Disposition, 1998) gave minoxidil 5 mg by mouth to eight mild cirrhotics and eight healthy subjects. For unchanged minoxidil, "the serum elimination rate constant was significantly smaller and mean residence time was significantly longer in cirrhotic patients".5

The chart is a model built on the app's half-life of 4.2 hours and time to peak of 1 hour. The once-daily interval is the one used in the randomized trial and the open-label study described below.6,7

Level over 5 days

Interval between doses

Level, as a share of the peak after one 5 mg dose

As studied: every day6.

An illustration from a pharmacokinetic model using a half-life of 4.2 hours. It is not a measured level or a suggested dose.

4

Human studies

The studies below are of low-dose oral minoxidil for hair loss, which the label calls an unapproved use.1

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Penha and colleagues, 20246Double-blind, placebo-controlled randomized trial at one clinic in Brazil, oral against topical minoxidil90 men enrolled, aged 18 to 55 with androgenetic alopecia (Norwood-Hamilton 3V to 5V); 68 completedOral minoxidil 5 mg daily with topical placebo, or topical minoxidil 5% 1 mL twice daily with oral placebo; 24 weeksBetween-group change in terminal hair density: frontal 3.1 hairs per cm2 (95% CI -18.2 to 21.5; P = .27), vertex 23.4 (95% CI -0.3 to 43.0; P = .09). Hypertrichosis 22 of 45 (49%) and headache 6 of 45 (14%) in the oral group.
Asilian and colleagues, 20248Randomized controlled trial, oral against topical minoxidil65 patients with androgenetic alopeciaOral minoxidil 1 mg per day or 5% topical solution; 6 monthsHair diameter improved in both groups (p < 0.001) with no significant difference between them. Hair density at three marked points improved significantly in the topical group (p = 0.025, 0.034, 0.014) but not the oral group; the difference between the two groups was not significant.
Sobral and colleagues, 20259Meta-analysis of randomized trials of oral minoxidil against topical solution; PubMed, Embase and Cochrane searched4 randomized trials, 279 patients with androgenetic alopeciaFollow-up 24 to 39 weeksHair density SMD 0.02 (95% CI -0.25 to 0.29) and hair diameter SMD -0.25 (95% CI -0.75 to 0.26). Hypertrichosis higher with oral minoxidil (RR 2.01; 95% CI 1.18-3.41); hypotension RR 2.42 (95% CI 0.26-22.46), not statistically significant.
Panchaprateep and Lueangarun, 20207Open-label, prospective, single-arm study in Bangkok30 men aged 24 to 59 with androgenetic alopecia (types III vertex to V); all 30 completedOral minoxidil 5 mg once daily; 24 weeksTotal hair count rose at weeks 12 and 24 (both p = 0.007). Hypertrichosis in 93% and pedal edema in 10%; no serious cardiovascular adverse events reported; slight alanine aminotransferase rises in 9 patients (30%). No comparison group.
Vañó-Galván and colleagues, 202110Retrospective multicenter study, no control group1404 patients treated for at least 3 months for any type of alopecia (943 women, 461 men), mean age 43Low-dose oral minoxidil, titrated in 1065 patients (2469 cases analysed)Hypertrichosis 15.1%; lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%; no life-threatening adverse effects observed.
Jimenez-Cauhe and colleagues, 202411Retrospective multicenter study in hypertension or arrhythmia254 patients with hypertension (the title counts 264 patients), mean age 56.9, on a mean of 1.45 antihypertensive drugsLow-dose oral minoxidil; 382 doses analysed in the 128 patients whose dose was titratedSystemic adverse effects in 26 cases (6.8%), including lightheadedness 3.1% and fluid retention 2.6%; discontinuation in 6 cases (1.5%).

Deeper analysis: Penha and colleagues, JAMA Dermatology, 2024

Penha, Miot, Kasprzak and Müller Ramos report a double-blind, placebo-controlled randomized trial at one specialized clinic in Brazil, with data collected from January to December 2021.6 Eligible men were aged 18 to 55 with androgenetic alopecia rated 3V, 4V or 5V on the Norwood-Hamilton scale, and were randomized 1:1 to oral minoxidil 5 mg daily with a topical placebo, or topical minoxidil 5% twice daily with an oral placebo, for 24 weeks.6 The primary outcome was change in terminal hair density on the frontal and vertex regions of the scalp.6 Of 90 enrolled participants, 68 completed the study; the source gives group sizes of 33 in the oral group and 35 in the topical group, alongside adverse event counts out of 45 in the oral group.6

The between-group differences in terminal hair density were not statistically significant in either region (frontal P = .27, vertex P = .09). Total hair density, a secondary outcome, also did not differ: frontal 2.6 hairs per cm2 (95% CI -10.3 to 15.8; P = .32) and vertex 5.5 (95% CI -12.5 to 23.5; P = .32). On photographic analysis, "oral minoxidil was superior to topical minoxidil on the vertex (24%; 95% CI, 0 to 48; P = .04) but not on the frontal scalp (12%; 95% CI, -12 to 36; P = .24)".6 The authors conclude that oral minoxidil 5 mg once per day for 24 weeks "did not demonstrate superiority over topical minoxidil, 5%, twice per day in men with AGA".6 In the oral group, hypertrichosis occurred in 22 of 45 (49%) and headache in 6 of 45 (14%).6

The study was supported by the Brazilian Dermatology Society Support Fund (FUNADERM), and the funder "had no role in the design and conduct of the study".6 Penha reported grants from FUNADERM during the study and no other disclosures were reported; one of the four authors is affiliated with TrichoLAB GmbH, Warsaw.6 The trial was registered with the Brazilian Registry of Clinical Trials (RBR-252w9r).6

Deeper analysis: Vañó-Galván and colleagues, Journal of the American Academy of Dermatology, 2021

This is a retrospective multicenter study of 1404 patients (943 women and 461 men, mean age 43, range 8 to 86) treated with low-dose oral minoxidil for at least 3 months for any type of alopecia; the dose was titrated in 1065 patients, which allowed 2469 cases to be analysed.10 Its authors include groups at Ramón y Cajal University Hospital in Madrid and Sinclair Dermatology in Melbourne.10 The study's stated objective was to describe safety.10

"The most frequent adverse effect was hypertrichosis (15.1%), which led to treatment withdrawal in 14 patients (0.5%)." Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%) and insomnia (0.2%), "leading to drug discontinuation in 29 patients (1.2%)", and "No life-threatening adverse effects were observed."10 The authors conclude that "only 1.7% of patients discontinued treatment owing to adverse effects".10 Their stated limitations are "Retrospective design and lack of a control group."10 The PubMed entry for the study records the conflicts of interest as "None disclosed" and lists no funding source.10

Deeper analysis: Panchaprateep and Lueangarun, Dermatology and Therapy, 2020

Thirty men aged 24 to 59 with androgenetic alopecia (modified Norwood-Hamilton types III vertex, IV and V) at King Chulalongkorn Memorial Hospital, Bangkok, took oral minoxidil 5 mg once daily for 24 weeks in an open-label, single-arm study; the primary outcome was vertex hair count at weeks 12 and 24.7 Total hair counts rose at weeks 12 and 24 (both p = 0.007), and the authors report a mean change in total hair counts of +19.23% from baseline at week 24.7

Safety findings: hypertrichosis in 28 patients (93.3%) at 24 weeks and pedal edema in three (10%) that "spontaneously resolved after 2–3 months"; orthostatic hypotension after the first dose in two patients (6.7%) at 30 minutes and one (3.3%) at 60 minutes, without symptoms; abnormal electrocardiogram findings in six patients (20%), two with occasional premature ventricular contraction and four with new T wave inversion in one lead.7 The authors write: "A limitation of the current study is that it was neither randomized nor controlled but rather an open-label clinical trial. A study population of 30 patients can be considered to be a relatively small sample."7 The study was funded by the Ratchadapisek Sompoch Endowment Fund, Chulalongkorn University, and the Pericardia Program of The Royal College of Physicians of Thailand, and both authors report nothing to disclose.7

5

Doses reported in studies and on labels

The app's typical dose is 2.5 to 5 mg per day. The label's dosage range is for hypertension, and the hair loss doses are those the studies reported.1

Table 5.1Doses reported in studies and on labels6 rows
SourceWhoDose reportedLength
US tablet label1Patients over 12 years with hypertension5 mg as a single daily dose to start; increases to 10, 20 and then 40 mg in single or divided doses are described; "The effective dosage range is usually 10 to 40 mg per day. The maximum recommended dosage is 100 mg per day."Not stated
US tablet label1Tablet strengths of this product2.5 mg and 10 mg tabletsNot applicable
Penha and colleagues, 20246Men with androgenetic alopecia5 mg daily24 weeks
Panchaprateep and Lueangarun, 20207Men with androgenetic alopecia5 mg once daily24 weeks
Asilian and colleagues, 20248Patients with androgenetic alopecia1 mg per day6 months
Jimenez-Cauhe and colleagues, 20202Patients across eight types of alopeciaBetween 0.25 and 5 mgVaried by study

In the label, for hypertension

  • The label's opening warning states that minoxidil tablets contain "the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects" and that it "can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated."1
  • Pericardial effusion, occasionally with tamponade, "has been observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function", and "Temporary edema developed in 7% of patients who were not edematous at the start of therapy."1
  • Hypertrichosis is "seen in about 80% of patients taking minoxidil tablets" and "develops within 3 to 6 weeks after starting therapy"; the label adds that on discontinuation "new hair growth stops, but 1 to 6 months may be required for restoration to pretreatment appearance."1
  • The label also lists "Minoxidil increases the heart rate", rashes including "rare reports of bullous eruptions, toxic epidermal necrolysis, and Stevens-Johnson Syndrome", and, rarely, thrombocytopenia and leukopenia.1
  • In animals the label reports cardiac lesions: "Minoxidil produces several cardiac lesions in animals." It adds that they "have not been recognized in patients treated with oral minoxidil at systemically active doses, despite formal review of over 150 autopsies of treated patients."1

In studies of low-dose oral minoxidil for hair loss

  • Vañó-Galván and colleagues (1404 patients): hypertrichosis 15.1%, with treatment withdrawal in 14 patients (0.5%); lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital edema 0.3% and insomnia 0.2%, with drug discontinuation in 29 patients (1.2%).10
  • Jimenez-Cauhe and colleagues, systematic review (442 patients): hypertrichosis 24%; all doses had an increased odds ratio of hypertrichosis compared with 0.25 to 0.5 mg (P < .001); pedal edema (2%) was associated with higher doses (P = .009); postural hypotension 1.1% and heart rate alterations 1.3%.2
  • Jimenez-Cauhe and colleagues, hypertension or arrhythmia: "Prior treatment with doxazosin (P<0.001), or with three or more antihypertensive drugs (P=0.012) was associated with a higher risk of discontinuation of LDOM."11
  • Penha and colleagues (oral 5 mg against topical): hypertrichosis 22 of 45 (49%) and headache 6 of 45 (14%) in the oral group; Sobral and colleagues pooled four randomized trials and reported hypertrichosis higher with oral minoxidil (RR 2.01) and no statistically significant difference in hypotension (RR 2.42; 95% CI 0.26-22.46).6,9
7

Bloodwork and markers

The label lists these findings in patients treated for hypertension: "Changes in direction and magnitude of the ECG T-waves occur in approximately 60% of patients treated with minoxidil"; hematocrit, hemoglobin and erythrocyte count "usually fall about 7% initially and then recover to pretreatment levels"; and "Serum creatinine increased an average of 6% and BUN slightly more, but later declined to pretreatment levels." For the T-wave changes it adds that they "usually disappear with continuance of treatment" and "appear to be nonspecific and without identifiable clinical significance".1

In the 30-man open-label study, laboratory evaluation covered blood count, urea, creatinine, electrolytes and liver function tests, with chest X-ray and electrocardiography. At 24 weeks blood count, urea, creatinine and electrolytes were within normal limits in all patients, aspartate aminotransferase was slightly raised in one patient (3.3%) and alanine aminotransferase in nine (30%), both at 40 to 60 U/L, and one patient (3.3%) showed a borderline heart size on chest X-ray; the authors also state that no abnormal laboratory findings were observed. Abnormal electrocardiogram findings occurred in six patients (20%).7 After the first 5 mg dose mean blood pressure went from 134.2/78 to 131.7/78.5 mmHg and mean pulse rate from 75.6 to 71.8 per minute at 60 minutes (P > 0.05), and at 24 weeks mean blood pressure changed non-significantly from 134.2/78 to 130.3/76.9 mmHg.7

8

Regulatory and anti-doping status

In the United States the tablet label's indication is hypertension, and the label states that using minoxidil tablets "in any formulation, to promote hair growth is not an approved indication."1

Minoxidil is not named in the text of the World Anti-Doping Agency's 2026 Prohibited List: a search of the list's text for "minoxidil" returned 0 matches, and the search covered that name only.12

9

Storage and handling

Sources in this part

  1. 1NuCare Pharmaceuticals, 2024

The label for the 2.5 mg tablets lists storage at "20° to 25°C (68° to 77°F)".1

Panchaprateep and Lueangarun write that "randomized, double-blind, placebo-controlled studies with longer study period are required to accurately identify the efficacy and long-term safety of low-dose oral minoxidil for the treatment of AGA."7 The systematic review of Jimenez-Cauhe and colleagues states that "Efficacy of OM could not be analyzed due to heterogeneous studies." It adds that four studies of oral minoxidil in androgenetic alopecia "reported a clinical response in 70% to 100% of the patients".2 Follow-up in the four randomized trials pooled by Sobral and colleagues ranged from 24 to 39 weeks.9

The label states that "Clinical studies of minoxidil tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects", and that "There are no adequate and well controlled studies in pregnant women." It also notes that "Neonatal hypertrichosis has been reported following exposure to minoxidil during pregnancy."1

The studies above differ in who they enrolled (men only in two, men and women in others, patients with hypertension in one) and in dose.6,7,8,11

What is the half-life of oral minoxidil?

The average plasma half-life of oral minoxidil in man is 4.2 hours according to the US tablet label, which matches the app's figure of about 4.2 hours.1 The label adds that the extent and time-course of the blood pressure reduction "do not correspond closely to its concentration in plasma".1

How long does the effect of oral minoxidil last?

After an effective single oral dose in patients treated for hypertension, the label states that "The total duration of effect is approximately 75 hours."1 The label gives this as the duration of the blood pressure effect, and its plasma half-life figure is 4.2 hours.1

How quickly does oral minoxidil peak?

Plasma levels of the parent drug reach their maximum within the first hour according to the US tablet label, in line with the app's time to peak of about 1 hour.1 The label places the blood pressure minimum later, between 2 and 3 hours.1

What is the bioavailability of oral minoxidil?

The app lists 95%, and the US tablet label states an absorption figure instead: minoxidil is "at least 90% absorbed from the GI tract in experimental animals and man".1 A search of the label text for "bioavailab" returned 0 matches.1

Is oral minoxidil approved for hair loss?

Not on the US tablet label, which states that "Use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication."1 The label's indication is hypertension that is symptomatic or associated with target organ damage and not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs.1

Is oral minoxidil banned by WADA?

Minoxidil is not named in the text of the WADA 2026 Prohibited List: a search of the text for "minoxidil" returned 0 matches, and the search covered that name only.12

What are the side effects of low-dose oral minoxidil?

In the retrospective study of 1404 patients by Vañó-Galván and colleagues, hypertrichosis was the most frequent adverse effect (15.1%), and systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%) and tachycardia (0.9%).10 Drug discontinuation occurred in 29 patients (1.2%) for systemic effects and treatment withdrawal in 14 (0.5%) for hypertrichosis, the authors state that 1.7% of patients discontinued treatment owing to adverse effects, no life-threatening adverse effects were observed, and the study had no control group.10

Does oral minoxidil work better than topical minoxidil?

In the 90-man randomized trial by Penha and colleagues, oral minoxidil 5 mg daily "did not demonstrate superiority over topical minoxidil, 5%" after 24 weeks, although on photographic analysis of the vertex oral minoxidil was superior (24%; 95% CI, 0 to 48; P = .04) and on the frontal scalp it was not.6 A meta-analysis of four randomized trials (279 patients) reported no differences in hair density (SMD 0.02; 95% CI -0.25 to 0.29) and a higher incidence of hypertrichosis with oral minoxidil (RR 2.01).9

What doses of oral minoxidil have been used in studies?

A systematic review of 14 studies reported doses between 0.25 and 5 mg for alopecia, with 5 mg daily used in the Penha trial and 1 mg per day in the Asilian trial.2,6,8 The app's typical dose is 2.5 to 5 mg per day, and the label's range for hypertension is usually 10 to 40 mg per day.1

13

References

  1. NuCare Pharmaceuticals, Inc. MINOXIDIL tablet. Prescribing information (manufactured for Teva Pharmaceuticals), revised 2/2024. DailyMed label
  2. Jimenez-Cauhe J, et al. Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. Dermatol Ther 2020. PMID 32757405
  3. Pietrauszka K, Bergler-Czop B. Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Postepy Dermatol Alergol 2022. PMC9326921
  4. Jimenez-Cauhe J, et al. Hair follicle sulfotransferase activity and effectiveness of oral minoxidil in androgenetic alopecia. J Cosmet Dermatol 2024. PMID 39034734
  5. Adams MH, et al. Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers. Biopharm Drug Dispos 1998. PMID 9840212
  6. Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol 2024. PMC11007651
  7. Panchaprateep R, Lueangarun S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther (Heidelb) 2020. PMC7649170
  8. Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: A randomized controlled trial. J Cosmet Dermatol 2024. PMID 38031516
  9. Sobral MVS, et al. Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials. Int J Dermatol 2025. PMID 39425514
  10. Vañó-Galván S, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol 2021. PMID 33639244
  11. Jimenez-Cauhe J, et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr 2024. PMID 37652097
  12. World Anti-Doping Agency. Prohibited List 2026. World Anti-Doping Code International Standard, in force 1 January 2026. WADA 2026 list